Galapagos receives transparency notification and 13D filing from Tang Capital

Core Points - Galapagos NV received a transparency notification from Tang Capital, indicating that Tang Capital and its affiliates hold a total of 3,323,407 voting rights, representing 5.04% of Galapagos' outstanding shares [1] - Tang Capital Management filed a Schedule 13D with the SEC, reporting beneficial ownership of 4,910,525 voting rights, which is 7.5% of Galapagos' outstanding shares, including ordinary shares and American Depository Receipts (ADRs) [2] - The notification specifies that Tang Capital and its affiliates can exercise voting rights at their discretion in the absence of specific instructions [1] Company Overview - Galapagos is a biotechnology company focused on transforming patient outcomes through innovative science and technology, addressing high unmet medical needs [4] - The company aims to create a deep pipeline of best-in-class medicines and is committed to delivering results for patients, employees, and shareholders [4] - Galapagos operates in Europe and the U.S., with capabilities ranging from lab to patient, including a decentralized cell therapy manufacturing platform [4]